Today, Colorado Center on Law and Policy (CCLP) and the National Health Law Program (NHeLP) filed a complaint with the U.S. Department of Health and Human Services Office for Civil Rights and the U.S. Department of Justice.
Bethany Pray provided testimony for Senate Bill 24-093, Continuity of Health-Care Coverage Change. CCLP is in support of SB24-093.
CCLP Policy Fellow, Milena Castañeda testified at the Medical Services Board meeting regarding emergency rules for the NEMT.
Chaer Robert provided testimony against House Bill 24-1065, Reduction of State Income Taxes. CCLP is in opposition of HB24-1065.
Bill offers Rx for drug-price transparency
The high cost of prescription drugs is driving health insurance premiums higher, and financially draining consumers and their families who rely on these medications. In fact, one in 10 Coloradans don’t fill their prescriptions due to costs. Meanwhile, prescription drugs account for 22 cents of every premium dollar spent on health care.
Unfortunately, despite a high-profile case of the pharmaceutical company Mylan overcharging Medicaid programs by billions of dollars and inexplicably raising the price of its life-saving emergency allergy injector, EpiPen, by 400 percent, health care consumers aren’t any closer to understanding why certain drugs cost so much.
In response to the financial pressures many Coloradans and Colorado businesses face over high drug costs, Rep. Joann Ginal, D-Fort Collins and Rep. Dominique Jackson, D-Aurora in the House and Sen. Dominick Moreno, D-Commerce City, in the Senate, are sponsoring House Bill 1260, or the Prescription Drug Price Transparency Act of 2018. HB 1260 would require insurance carriers to provide information on the top 25 costliest and most prescribed drugs in Colorado as well as the drugs that have the highest year-to-year price increases. If approved, the legislation will help Coloradans understand how prescription drugs are contributing to their premium hikes. In addition, the bill requires 90 days advance public notice when drug prices are increasing, and requires drug companies to provide an explanation on price increases that exceed 10 percent in the previous two years. Pricing transparency will give insurance carriers more leverage to negotiate with the pharmaceutical companies — fostering a more competitive market that would ultimately benefit businesses and consumers.
The legislation was developed by a coalition of consumer groups with support from health insurance carriers, health care providers, public health officials and other policy advocates. According to a recent poll conducted by Magellan for Healthier Colorado, 83 percent of Coloradans say drug prices are too high, and 94 percent think the public should have access to information about the basis for drug costs.
Nobody should have to choose between affording a life-changing drug and putting food on the table for their family. While there is no single solution to out-of-control pricing, giving the public and Colorado leaders access to information is a crucial first step.”
HB 1260 will be heard by the House Health, Insurance & Environment Committee.
– By Bob Mook